Publication:
Phosphate control in reducing FGF23 levels in hemodialysis patients.

dc.contributor.authorRodelo-Haad, Cristian
dc.contributor.authorRodriguez-Ortiz, Maria E
dc.contributor.authorMartin-Malo, Alejandro
dc.contributor.authorPendon-Ruiz de Mier, M Victoria
dc.contributor.authorAgüera, M Luisa
dc.contributor.authorMuñoz-Castañeda, Juan R
dc.contributor.authorSoriano, Sagrario
dc.contributor.authorCaravaca, Francisco
dc.contributor.authorAlvarez-Lara, M Antonia
dc.contributor.authorFelsenfeld, Arnold
dc.contributor.authorAljama, Pedro
dc.contributor.authorRodriguez, Mariano
dc.contributor.funderNational Institute of Health Carlos III
dc.contributor.funderConsejeria de Salud of Junta de Andalucía
dc.contributor.funderMonardes Programme from Consejeria de Salud-SAS (Junta de Andalucía)
dc.date.accessioned2023-01-25T10:21:19Z
dc.date.available2023-01-25T10:21:19Z
dc.date.issued2018-07-04
dc.description.abstractIn hemodialysis patients, high levels of Fibroblast Growth Factor 23 (FGF23) predict mortality. Our study was designed to test whether the control of serum phosphate is associated with a reduction in serum FGF23 levels. Additionally other variables with a potential effect on FGF23 levels were evaluated. The effect of sustained (40-weeks) control of serum phosphate on FGF23 levels (intact and c-terminal) was evaluated in 21 stable hemodialysis patients that were not receiving calcimimetics or active vitamin D. Patients received non-calcium phosphate binders to maintain serum phosphate below 4.5 mg/dl. In an additional analysis, values of intact-FGF23 (iFGF23) and c-terminal FGF23 (cFGF23) from 150 hemodialysis patients were correlated with parameters of mineral metabolism and inflammation. Linear mixed models and linear regression were performed to evaluate longitudinal trajectories of variables and the association between FGF23 and the other variables examined. During the 40-week treatment, 12 of 21 patients achieved the target of serum phosphate 4.5 mg, iFGF23 and cFGF23 increased two and four-fold respectively as compared with baseline. Furthermore, changes in serum phosphate correlated with changes in C-reactive protein (hs-CRP). In our 150 hemodialysis patients, those in the higher tertile of serum phosphate also showed increased hs-CRP, iPTH, iFGF23 and cFGF23. Multiple regression analysis revealed that iFGF23 levels directly correlated with both serum phosphate and calcium, whereas cFGF23 correlated with serum phosphate and hs-CRP but not with calcium. The control of serum phosphate reduced iFGF23. This reduction was also associated with a decreased in inflammatory parameters. Considering the entire cohort of hemodialysis patients, iFGF23 levels correlated directly with serum phosphate levels and also correlated inversely with serum calcium concentration. The levels of cFGF23 were closely related to serum phosphate and parameters of inflammation.
dc.description.versionSi
dc.identifier.citationRodelo-Haad C, Rodríguez-Ortiz ME, Martin-Malo A, Pendon-Ruiz de Mier MV, Agüera ML, Muñoz-Castañeda JR, et al. Phosphate control in reducing FGF23 levels in hemodialysis patients. PLoS One. 2018 Aug 7;13(8):e0201537
dc.identifier.doi10.1371/journal.pone.0201537
dc.identifier.essn1932-6203
dc.identifier.pmcPMC6080760
dc.identifier.pmid30086150
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080760/pdf
dc.identifier.unpaywallURLhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0201537&type=printable
dc.identifier.urihttp://hdl.handle.net/10668/12812
dc.issue.number8
dc.journal.titlePloS one
dc.journal.titleabbreviationPLoS One
dc.language.isoen
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Reina Sofía
dc.page.number23
dc.publisherPublic Library of Science
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.relation.projectIDFIS 14/00638
dc.relation.projectIDFIS 17/01785
dc.relation.projectIDFIS 17-01010
dc.relation.projectIDPI0311-2014
dc.relation.projectIDPI-0136-2016
dc.relation.publisherversionhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0201537
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.decsAnciano de 80 o más años
dc.subject.decsAnálisis de Supervivencia
dc.subject.decsCalcio
dc.subject.decsDiálisis renal
dc.subject.decsFactores de frecimiento de fibroblastos
dc.subject.decsHiperfosfatemia
dc.subject.decsInsuficiencia renal crónica
dc.subject.decsQuelantes
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshC-reactive protein
dc.subject.meshCalcium
dc.subject.meshChelating agents
dc.subject.meshCross-sectional studies
dc.subject.meshFemale
dc.subject.meshFibroblast growth factor-23
dc.subject.meshFibroblast growth factors
dc.subject.meshHumans
dc.subject.meshHyperphosphatemia
dc.subject.meshLongitudinal studies
dc.subject.meshMale
dc.subject.meshMiddle aged
dc.subject.meshPhosphates
dc.subject.meshProspective studies
dc.subject.meshRenal dialysis
dc.subject.meshRenal insufficiency, chronic
dc.subject.meshSurvival analysis
dc.subject.meshTreatment outcome
dc.titlePhosphate control in reducing FGF23 levels in hemodialysis patients.
dc.typeResearch article
dc.type.hasVersionVoR
dc.volume.number13
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
PMC6080760.pdf
Size:
1.56 MB
Format:
Adobe Portable Document Format
No Thumbnail Available
Name:
Rodelo-Haad_PhosphateControl_MaterialSuplementario.zip
Size:
656.64 KB
Format: